期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Docetaxel治疗激素非依赖性前列腺癌的应用进展

Progress in Doctaxel for the Treatment of Hormone-independent Prostate Cancer
暂未订购
导出
摘要 激素非依赖性前列腺癌是泌尿糸肿瘤学中最为复杂的问题之一。Docetaxel通过诱导肿瘤细胞凋亡可达到抗肿瘤作用,因其独特的作用机制和良好的耐受性,已被广泛用于和蒽环类、吉西他滨、铂类等联合应用。该文就Docetaxel在激素非依赖性前列腺癌治疗中的进展综述如下。
作者 汪芬妹 张琦
机构地区 绍兴第二人民医院 浙江大学医学院
出处 《肿瘤学杂志》 CAS 2007年第5期419-423,共5页 Journal of Chinese Oncology
关键词 前列腺肿瘤 DOCETAXEL 激素非依赖性
分类号 R737.25 [医药卫生—肿瘤]
  • 相关文献

参考文献32

  • 1Berry W, Eisenberger M. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy [J]. Oncologist, 2005, 10(Suppl 3) : 30-39.
  • 2Pienta K J, Smith DC. Advances in prostate cancer chemotherapy:a new era begins [J]. CA Cancer J Clin, 2005, 55(5): 300-318.
  • 3Hainsworth JD, Burris HA, Erland JB, et al. Phase Ⅰ trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer[J]. J Clin Oncol, 1998, 16 (6):2164-2168.
  • 4Beer TM, Pierce WC, Lowe BA, et al. Phase Ⅱ study of weekly docetaxel in symptomatic androgen-independent prostate cancer[J]. Ann Oncol, 2001, 12(9):1273-1279.
  • 5Ferrero JM,Foa C, Thezenas S, et al. A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer [J]. Oncology, 2004, 66(4):281-287.
  • 6Berry W, Dakhil S, Gregurich MA, et al. Phase Ⅱ trial of single-agent weekly docetaxel in hormone-refractory,symptomatic, metastatic carcinoma of the prostate [J]. Semin Oncol, 2001, 28(4 Suppl 15):8-15.
  • 7Gravis G, Bladou F, Salem N, et al. Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma[J]. Cancer, 2003, 98(8):1627-1634.
  • 8Petrioli R,Pozzessere D,Messinese S,et al.Weekly low-dose docetaxel in advanced hormone-resistant prostate cancer patients previously exposed to chemotherapy[J]. Oncology, 2003, 64(4):300-305.
  • 9Fossa SD,Jacobsen AB, Ginman C, et al. Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase Ⅱ study[J]. Eur Urol, 2007, Feb 8 ; [Epub ahead of print].
  • 10Collins R, Fenwick E, Trowman R, et al. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer[J]. Health Technol Assess, 2007, 11(2) : iii-iv,xv-xviii, 1-179.

二级参考文献21

  • 1Liao M. Some features of lung cancer in China. Lung Cancer,1993,10(1-2) : 107 116.
  • 2Johnson DH, Einhorn LH, Bartolucci A, et al. Thoracic radiotherapy does not prolong survival in patients with locally advanced,unresectable non-small cell lung cancer. Ann Intern Med, 1990,113(1) : 33-38.
  • 3Perez CA, Pajak TF, Rubin P, et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer, 1987, 59(11):1874-1881.
  • 4Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ,1995,311(7010):899-909.
  • 5Byhardt RW, Scott C, Sause WT, et al. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys,1998,42(3) : 469-478.
  • 6Furuse K, Fukuoka M, Takada H, et al. Phase Ⅲ study of concurrent versus sequential thoracic radiotherapy in combination with mitomycine, vindesine and cisplatin in unresectable stage Ⅲ non-small-cell lung cancer: five-year median follow-up results. Proc Am Soc Clin Oncol,1999,18 : 458.
  • 7Soto Parra H, Cavina R, Latteri F, et al. Three-week versus fourweek schedule of cisplatin and gemcitabine: resuhs-of a randomized phase Ⅱ study. Ann Oncol,2002,13(7):1080-1086.
  • 8Abratt RP, Bezwoda WR, Falkson G, et al. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase Ⅱ study. J Clin Oncol,1994,12(8) : 1535-1540.
  • 9Langer CJ. The role of new agents in advanced non-small-cell lung carcinoma. Curr Oncol Rep,2000,2(1) : 76-89.
  • 10Bunn PA Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res, 1998,4(5) : 1087-1100.

共引文献5

肿瘤学杂志
2007年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部